التفاصيل البيبلوغرافية
| العنوان: |
Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. |
| المؤلفون: |
Ielpo, B., Duran, H., Diaz, E., Fabra, I., Caruso, R., Ferri, V., Malavé, L., Hidalgo, M., Alvarez, R., Plaza, C., Quijano, Y., Vicente, E. |
| المصدر: |
European Journal of Surgical Oncology; Sep2016, Vol. 42 Issue 9, p1394-1400, 7p |
| مصطلحات موضوعية: |
PANCREATIC cancer treatment, PACLITAXEL, CANCER chemotherapy, ADENOCARCINOMA, CANCER treatment, DRUG efficacy, MEDICATION safety, PREOPERATIVE care |
| مستخلص: |
Introduction Recently, novel chemotherapeutic agents like nab-paclitaxel and gemcitabine demonstrated a survival benefit over gemcitabine alone in metastatic pancreatic cancer. However, there are limited clinical results using this chemotherapy in potentially resectable pancreatic adenocarcinoma. Our aim is to report the oncological results of patients affected by potentially resectable pancreatic adenocarcinoma that underwent surgery after a combination of gemcitabine and nab-paclitaxel. Methods A total of 25 patients have been included. We evaluated: (1) Drug toxicity; (2) tumoral response (tumoral size at CT scan, SUV of FDG PET-CT scan and CA 19.9; (3) resection rate; (4) R0 resection rate and histopathological response and (5) survival and disease free survival. Results Overall treatment was well tolerated. Treatment resulted in a statistical decrease of CA19-9 (p = 0.019) tumoral size (p = 0.04) and SUV (p = 0.004). The resection rate was 68% (17/25 patients). All specimens were R0 and 13 of 17 specimens had major pathological regressions (complete and important response). Median survival and medial disease free survival of patients that underwent surgery was 21 months and 19 months, respectively at a mean follow up of 38.5 months. Conclusions This data suggests that nab-paclitaxel and gemcitabine is a safe and effective neoadjuvant treatment for potentially resectable pancreatic adenocarcinoma. This promising data should be confirmed in larger, randomized studies. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Surgical Oncology is the property of W B Saunders and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
Full Text via ClinicalKey 
Full Text Finder